UC Davis Health Clinical Studies

Experimental TAS-102 and Irinotecan for Gastric and Gastroesophageal Adenocarcinoma (stomach cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this research study is to test the experimental combination of TAS-102 and irinotecan. We hope to learn if it is effective in patients with gastric or gastroesophageal cancers (GEC). Both TAS-102 and irinotecan are used to treat GEC and are included in treatment guidelines. Irinotecan is not approved to treat gastroesophageal cancers. TAS-102 was approved in 2019 for patients with advanced GEC who have no other standard chemotherapy options. This is the first study to test the combination of TAS-102 and irinotecan in advanced GEC. There has been a previous study using this combination in patients with metastatic colon cancer. It was shown to have some anti-tumor effects and the dose and schedule of the combination was shown to be tolerable. We would like to see if there are similar effects in patients with advanced GEC. The purpose of this research study is to see if the combination of TAS-102 and irinotecan can slow down tumor growth in patients.

Drug study, Phase 1
Any, age 18 years or older

A Study of Experimental ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma (liver cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to find out if Study Drug ET140202 T cells are safe and if there are beneficial effects in people with liver cancer. The investigational study drug is ET140202 T cells. The word “investigational” means the study drug is still being tested in research studies and is not approved by the FDA. Your ET140202 T cell product will be made from your own T cells, a specific type of white blood cell. Your T cells will be genetically-modified in the laboratory. This means the T cells are changed by inserting additional pieces of DNA (genetic material) into the cells. This makes them recognize and kill liver cancer cells. The process of making your ET140202 T cell product is described here: • Your cells will be collected by a procedure called leukapheresis. This involves collecting your blood and separating your white blood cells from other blood components. • Your T cells, a specific type of white blood cell, will be isolated and grown in the laboratory. • Your T cells will be treated with a vector. Vectors are type of virus that can enter cells and can change the way the cell acts. • After adding the new ET140202-specific genetic material, your ET140202 T cells will be grown to larger numbers. Afterwards, the cells are washed to select the best cells and frozen. • Your ET140202 T cells will be tested to make sure they are safe for use and then administered to you.

Biological study, Phase [/1/,/ /2/]
Any, age 18 years or older

A Study of Engineered Donor Grafts (TregGraft) for Allogeneic Transplantation for Hematologic Malignancies (blood cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in a research study of a type of blood stem cell transplant called TregGraft. TregGraft is being tested as a possible treatment of blood cancers and conditions highly likely to turn into blood cancer. TregGraft is an experimental therapy, meaning that it is not approved by the FDA. TregGraft is the study treatment in this research study. You will not receive TregGraft. Rather, it is the blood cell transplant that will be given to the recipient and will be made from your blood cells. A key part of TregGraft are healthy blood-forming cells. These will be isolated from your blood cells. When placed in the recipient’s bloodstream, they will grow and make new healthy red blood cells, white blood cells, and platelets. TregGraft also includes other specific white blood cell populations including regulatory T cells. These will also be isolated from your blood cells. When given to transplant recipients, they may prevent some of the known complications of blood cell transplants. One example is graft-versus-host disease (GVHD), a condition that involves the immune attack on recipient tissues by donor cells. TregGraft also includes “conventional” T cells, that may help fight infection or cancer, but also carry a risk of causing GVHD.

Biological study, Phase 1
Any, age 18 to 65 years old

Study on Experimental Olaparib Plus Abiraterone for Metastatic Castration-resistant Prostate Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This research study is for patients who have metastatic Castration-resistant Prostate Cancer (mCRPC). The reason for the study is to find a more effective treatment for this disease. The research team hopes to find out if an experimental medication called olaparib is safe and effective. It will be tested in patients who are also given abiraterone treatment. Olaparib (tradename Lynparza™) is approved by the FDA for other types of cancer. It is considered experimental in this study. Abiraterone is already an approved medication for the treatment of some patients with prostate cancer.

Drug study, Phase 3
Male, age 18 to 99 years old

A Study of Experimental AB-205 in Adults With Lymphoma Undergoing Autologous (from self) Stem Cell Transplantation

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are invited to be in this study because you have lymphoma. A clinical trial is a type of research study. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer. Clinical trials include only people who choose to take part. This is a first in-human study. The purpose of this research is to find out if the experimental product, AB-205, is safe. AB-205 is made up of engineered (modified) human endothelial cells. The endothelial cells are cells that line the inside of blood vessels including the umbilical cord. AB-205 is made from human umbilical endothelial cells that are collected from the umbilical cord of a healthy newborn baby. This research study will test the safety of a single dose infusion of AB-205, given after a bone marrow transplant. The study goal is to test the highest dose of AB-205 to be given in humans with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL). Patients are in a chemo-sensitive remission undergoing high-dose therapy (HDT), with or without radiation. Participants have an autologous stem cell transplant. This is a type of transplant in which a person’s own stem cells are taken, preserved and returned to them.

Biological study, Phase 1
Any, age 18 years or older
Loading